Search

Your search keyword '"Park, Jae H"' showing total 1,277 results

Search Constraints

Start Over You searched for: Author "Park, Jae H" Remove constraint Author: "Park, Jae H"
1,277 results on '"Park, Jae H"'

Search Results

1. Conventional and novel [18F]FDG PET/CT features as predictors of CAR-T cell therapy outcome in large B-cell lymphoma

2. Biomarkers and cardiovascular outcomes in chimeric antigen receptor T-cell therapy recipients.

4. CD19 CAR T-cell therapy and prophylactic anakinra in relapsed or refractory lymphoma: phase 2 trial interim results

5. Enhanced clinical assessment of hematologic malignancies through routine paired tumor and normal sequencing

6. Two-year follow-up of KTE-X19 in patients with relapsed or refractory adult B-cell acute lymphoblastic leukemia in ZUMA-3 and its contextualization with SCHOLAR-3, an external historical control study

8. Impact of prior inotuzumab ozogamicin treatment on brexucabtagene autoleucel outcomes in adults with B-cell ALL

11. Author Correction: Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy

12. Chimeric Antigen Receptor T-Cell Therapy for Cancer and Heart: JACC Council Perspectives.

13. Tracking the evolution of therapy-related myeloid neoplasms using chemotherapy signatures

14. A first-in-human phase 1, multicenter, open-label study of CB-012, a next-generation CRISPR-edited allogeneic anti-CLL-1 CAR-T cell therapy for adults with relapsed/refractory acute myeloid leukemia (AMpLify).

15. Obecabtagene autoleucel (obe-cel, AUTO1) in adults with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL): Overall survival (OS), event-free survival (EFS) and the potential impact of chimeric antigen receptor (CAR)-T cell persistency and consolidative stem cell transplantation (SCT) in the open-label, single-arm FELIX phase Ib/II study.

16. Long-term survival outcomes of patients (pts) with relapsed or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) treated with brexucabtagene autoleucel (brexu-cel) in ZUMA-3.

17. Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy

19. The role of allogeneic transplant for adult Ph+ ALL in CR1 with complete molecular remission: a retrospective analysis

21. Consensus opinion from an international group of experts on measurable residual disease in hairy cell leukemia

24. CAR-engineered lymphocyte persistence is governed by a FAS ligand/FAS auto-regulatory circuit

27. Impact of Tocilizumab on CAR-T Cells Outcome and Toxicity: Results from a Large B Cell Lymphoma Cohort

28. Site-Specific Response Rates in Large B-Cell Lymphomas Treated with CD19-CART Therapy.

29. Modified EASIX predicts severe cytokine release syndrome and neurotoxicity after chimeric antigen receptor T cells

31. KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study

32. KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results

33. Visualization of one-dimensional diffusion and spontaneous segregation of hydrogen in single crystals of VO2

35. Multiple isoforms of the Activin-like receptor baboon differentially regulate proliferation and conversion behaviors of neuroblasts and neuroepithelial cells in the Drosophila larval brain.

37. Allogeneic stem cell transplantation for chronic lymphocytic leukemia in the era of novel agents

38. Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies

39. Safety and activity of selinexor in patients with myelodysplastic syndromes or oligoblastic acute myeloid leukaemia refractory to hypomethylating agents: a single-centre, single-arm, phase 2 trial

42. Toxicity and response after CD19-specific CAR T-cell therapy in pediatric/young adult relapsed/refractory B-ALL

43. Therapy-related acute lymphoblastic leukemia is a distinct entity with adverse genetic features and clinical outcomes

47. Photoresponse of a strongly correlated material determined by scanning photocurrent microscopy

49. Vemurafenib and Obinutuzumab as Frontline Therapy for Hairy Cell Leukemia

50. Prospective analysis to determine barriers to allogeneic hematopoietic cell transplantation in patients with acute leukemia

Catalog

Books, media, physical & digital resources